US 12390509
Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof
granted A61KA61K38/1709A61K47/02
Quick answer
US patent 12390509 (Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof) held by Larimar Therapeutics, Inc. expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Larimar Therapeutics, Inc.
- Grant date
- Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 56
- CPC classes
- A61K, A61K38/1709, A61K47/02, A61K47/10, A61K47/12